FDA 483 - Emily A. DiMango, M.D. - August 13, 2024

An FDA inspection of Columbia University Medical Center in New York revealed a significant issue regarding the prompt reporting of serious adverse events. The facility failed to adhere to protocol requirements for timely submission of SAEs to the sponsor. This indicates a lapse in clinical trial oversight and patient safety reporting procedures.